MedDataX Logo

Genetics Study of In-stent Restenosis

NCT ID: NCT01670396

Last Updated: 2012-08-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-03-31

Study Completion Date

2012-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The investigators hypothesized that genetic variants of G protein influence the development of restenosis and clinical outcome of patients receiving drug-eluting stents (DES).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Bare -Metal Stents and Drug -Eluting Stents in the Treatment of Patients With Vertebral Artery Ostium Stenosis

NCT02197559

Ischemic Stroke
COMPLETED

Critical Treatment of Coronary Artery Disease

NCT03195621

Coronary Artery Disease Coronary Artery Disease Progression
COMPLETED NA

Matrix Metalloproteinases Expression in the Neointimal Hyperplasia Induced by Drug Eluting Stent (DES) Implantation

NCT03375528

Coronary Artery Disease Stent Restenosis
UNKNOWN NA

A Cohort Study of PCI Strategies for Severely Calcified Lesions of Complex Coronary Arteries in the Elderly

NCT06168422

Coronary Heart Disease
RECRUITING

Joint Inflation With Nominal-pressure and Stability Approach in DES Optimization

NCT06013007

Acute Coronary Syndrome De Novo Stenosis
UNKNOWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Although drug-eluting stents (DES) have reduced restenosis rates compared with bare-metal stents, the restenosis rate is still high in the high-risk group. G protein plays important roles in the signal transduction leading to vascular smooth muscle proliferation. The initial and subsequent studies suggest that the T allele of C825T polymorphism is associated with enhanced transmembrane signaling via Gi proteins.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

in-stent restenosis

No interventions assigned to this group

non-in-stent restenosis

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients who underwent follow-up angiography. All the patients must had been implanted with DES during the last two years.

Exclusion Criteria

* For the non-ISR group, the patients underwent follow-up angiography less than 6 months away from stent implanting.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Shanghai Zhongshan Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Zhongshan Hospital

Shanghai, , China

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Yamei Xu

Role: CONTACT

[email protected]
8613917133371

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Yamei Xu

Role: primary

[email protected]
8613917133371

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ZS-XN-ISR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Cortisone or Drug Eluting Stents (DES) as Compared to Bare Metal Stents (BMS) to EliminAte Restenosis
NCT00369356 COMPLETED PHASE2/PHASE3
Dexamethasone-Eluting Stent in Acute Coronary Syndrome to Prevent Restenosis
NCT00190099 COMPLETED PHASE4
Optimal Stent Deployment Strategy of Contemporary Stents
NCT05292651 RECRUITING NA
Coronary Non-slip Balloon Catheter in Patients With Coronary Artery Stenosis(CREST)
NCT05606367 UNKNOWN NA
OPtimal stEnt Deployment stRategy oF Contemporary sTents - Registry to Evaluate Percutaneous Coronary Intervention Using Bioresorbable Scaffolds With Thinner-strut Construction and Guidance by intracOronary Imaging to REduce Scaffold Failure
NCT06919562 NOT_YET_RECRUITING
Optical Coherence TomOgraphy Assessment of the Drug-Eluting Stent
NCT01012583 UNKNOWN
Intra-stent Tissue Evaluation Within BMS and DES > 3 Years Since Implantation
NCT01835301 UNKNOWN
Drug Coated Balloon Versus Stenting in Patients With Symptomatic Vertebral Artery Stenosis：an Observational Clinical Study
NCT03311360 COMPLETED
Compare the Safety and Effectiveness of Genoss® DCB and SeQuent® Please NEO in Chinese Patients with Coronary ISR
NCT04767022 COMPLETED NA
The 3D Stent Study
NCT06898021 RECRUITING
Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis
NCT00811772 COMPLETED NA
Vascular Response of Orsiro vs. Xience Drug-Eluting Stents for Treating Coronary Bifurcation Lesions
NCT05200637 UNKNOWN NA
OCT Based Edge and In-stent Vascular Response After Cordimax Stent in patIents With NSTE-ACS
NCT02868203 UNKNOWN PHASE4
Angina After PCI: a Systems Medicine Study
NCT06854302 ENROLLING_BY_INVITATION
Blood Endothelium Progenitor Cells and Dendritic Cells as Predictive Biomarkers of In-stent Restenosis
NCT00493597 COMPLETED
Bioabsorbable Versus Durable Polymer Drug Eluting Stent (DES): a Meta-analysis
NCT01466634 COMPLETED
Efficacy Study of Drug-eluting and Bare Metal Stents in Bypass Graft Lesions
NCT00611910 COMPLETED PHASE4
the Effect of Prolonged Inflation Time During Stents Deployment for ST-elevation Myocardial Infarction
NCT03199014 UNKNOWN NA
Retrospective Study of the Impact of Drug Eluting Stents
NCT00487604 UNKNOWN
ProStent Coronary Drug-Eluting Stent
NCT00887211 UNKNOWN NA
A Randomized, Multi-Center Study of the Pimecrolimus-Eluting and Pimecrolimus/Paclitaxel-Eluting Coronary Stent Systems (GENESIS)
NCT00322569 COMPLETED PHASE3
Intracoronary Stenting and Restenosis - Randomized Trial of Drug-eluting Stent Implantation or Drug-coated Balloon Angioplasty According to Neointima Morphology in Drug-eluting Stent Restenosis 5
NCT05544864 RECRUITING NA
Vascular Implant Safety and Efficacy Study
NCT03263858 COMPLETED NA
Progenitor Cells Role in Restenosis and Atherosclerosis
NCT01575431 COMPLETED
In-stent Restenosis in Patients With Patent Previous Bare Metal Stent
NCT01296399 COMPLETED